• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

W.L. Gore

W.L. Gore officials think they can spur insulin delivery system innovation

December 6, 2019 By Chris Newmarker

W.L. Gore PhysioLogic Devices

W.L. Gore announced this week that it is investing in PhysioLogic Devices, a startup developing an implantable intraperitoneal insulin delivery system. The size of the investment was not disclosed. But it was part of Gore’s Micro-Equity Investment (MEI) program, which provides investments of up to $500,000. W.L. Gore officials think the company’s more than 60 years […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: PhysioLogic Devices, W.L. Gore

Gore adds $10m to ViaCyte investment

September 25, 2018 By Brad Perriello

ViaCyte, W.L. Gore

W.L. Gore put up a $10 million convertible note for ViaCyte and the Type I diabetes treatment they’re working on. Last year the companies inked a deal to work on the synthetic pancreas ViaCyte is developing. The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup Tagged With: ViaCyte, W.L. Gore

ViaCyte looks to cell replacement therapy to cure Type I diabetes

May 22, 2017 By Sarah Faulkner

ViaCyte

ViaCyte said today that it will begin clinical trials of its novel islet cell replacement therapy in development as a potential cure for Type I diabetes, after landing regulatory wins from the FDA and Health Canada. The company’s PEC-Direct candidate delivers stem cell-derived pancreatic progenitor cells in a device that is designed to enable direct […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Stem Cells Tagged With: Juvenile Diabetes Research Foundation (JDRF), ViaCyte, W.L. Gore

ViaCyte, Gore ink co-development deal for synthetic pancreas

March 29, 2017 By Brad Perriello

ViaCyte, W.L. Gore

ViaCyte and W.L. Gore & Assoc. said today that they inked a co-development deal for the synthetic pancreas ViaCyte is developing to treat diabetes. The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the skin. The newly created pancreatic cells generate insulin and […]

Filed Under: Diabetes, Discovery, Drug-Device Combinations, Featured Tagged With: ViaCyte, W.L. Gore

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS